Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Interim Corp Controller & CAO | September 10, 2025 | September 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date September 10, 2025 · Filed September 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,259 |
Ending reported balance
After 2025-09-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-09-10 · Exercise / conversion · Acquired 921 · Balance 46,597 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Row 2 · 2025-09-10 · Tax withholding · Disposed 338 · Balance 46,259 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 7,864 |
Reported balance
After 2025-09-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-09-10 · Exercise / conversion · Disposed 921 · Balance 7,864 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IPI Legacy Liquidation Co
Report date April 05, 2024 · Filed April 09, 2024
Section 16 reporting ended · disclosed 2024-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.02 · Expires 2029-11-20 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-05 · Other · Disposed 31,356 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Liquidation of Impel Pharmaceuticals Inc., which was confirmed by the United States Bankruptcy Court for the Northern District of Texas on April 2, 2024, all of the Issuer's shares of its capital stock were canceled and extinguished effective April 5, 2024, and any rights of any holder in respect thereof were canceled without any recovery. F2: The option was fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.96 · Expires 2031-07-10 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-05 · Other · Disposed 11,500 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Liquidation of Impel Pharmaceuticals Inc., which was confirmed by the United States Bankruptcy Court for the Northern District of Texas on April 2, 2024, all of the Issuer's shares of its capital stock were canceled and extinguished effective April 5, 2024, and any rights of any holder in respect thereof were canceled without any recovery. F2: The option was fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2032-06-15 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-05 · Other · Disposed 12,789 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Liquidation of Impel Pharmaceuticals Inc., which was confirmed by the United States Bankruptcy Court for the Northern District of Texas on April 2, 2024, all of the Issuer's shares of its capital stock were canceled and extinguished effective April 5, 2024, and any rights of any holder in respect thereof were canceled without any recovery. F2: The option was fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-05 · Other · Disposed 13,222 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Liquidation of Impel Pharmaceuticals Inc., which was confirmed by the United States Bankruptcy Court for the Northern District of Texas on April 2, 2024, all of the Issuer's shares of its capital stock were canceled and extinguished effective April 5, 2024, and any rights of any holder in respect thereof were canceled without any recovery. F3: The option was scheduled to vest in full as of June 16, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the First Amended Joint Plan of Liquidation of Impel Pharmaceuticals Inc., which was confirmed by the United States Bankruptcy Court for the Northern District of Texas on April 2, 2024, all of the Issuer's shares of its capital stock were canceled and extinguished effective April 5, 2024, and any rights of any holder in respect thereof were canceled without any recovery.
F2: The option was fully vested.
F3: The option was scheduled to vest in full as of June 16, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2025 Filed Sep 11, 2025 23:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 921 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001374988-25-000005 · wk-form4_1757633641.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · Interim Corp Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,864 Underlying: Common Stock · 921 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 23:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 338 | $115.25 | $38,954.50 |
DisclosureSEC source: 0001374988-25-000005 · wk-form4_1757633641.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · Interim Corp Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,259 Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 23:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 921 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001374988-25-000005 · wk-form4_1757633641.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · Interim Corp Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 23:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-017339 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · Interim Corp Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,785 Underlying: Common Stock · 920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 23:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 340 | $110.09 | $37,430.60 |
DisclosureSEC source: 0001127602-25-017339 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · Interim Corp Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,676 Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 23:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-017339 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · Interim Corp Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 16:20 UTC | IPI Legacy Liquidation Co IMPLQ · Entity 15659 | OtherStock Option (right to buy) · Derivative | 13,222 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-24-010568 · form4-04092024_080446.xml · derivative · entry 4 Wilfong Diane E. · CIK 0001374988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,222 shares Expires 2033-06-15 F1 · kind: Pursuant to the First Amended Joint Plan of Liquidation of Impel Pharmaceuticals Inc., which was confirmed by the United States Bankruptcy Court for the Northern District of Texas on April 2, 2024, all of the Issuer's shares of its capital stock were canceled and extinguished effective April 5, 2024, and any rights of any holder in respect thereof were canceled without any recovery. F3 · derivative.exercise_date: The option was scheduled to vest in full as of June 16, 2024. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 16:20 UTC | IPI Legacy Liquidation Co IMPLQ · Entity 15659 | OtherStock Option (right to buy) · Derivative | 12,789 | $0.00 Strike: $8.65 | $0.00 |
DisclosureSEC source: 0001415889-24-010568 · form4-04092024_080446.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,789 shares Expires 2032-06-15 F1 · kind: Pursuant to the First Amended Joint Plan of Liquidation of Impel Pharmaceuticals Inc., which was confirmed by the United States Bankruptcy Court for the Northern District of Texas on April 2, 2024, all of the Issuer's shares of its capital stock were canceled and extinguished effective April 5, 2024, and any rights of any holder in respect thereof were canceled without any recovery. F2 · derivative.exercise_date: The option was fully vested. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 16:20 UTC | IPI Legacy Liquidation Co IMPLQ · Entity 15659 | OtherStock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001415889-24-010568 · form4-04092024_080446.xml · derivative · entry 2 Wilfong Diane E. · CIK 0001374988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,500 shares Expires 2031-07-10 F1 · kind: Pursuant to the First Amended Joint Plan of Liquidation of Impel Pharmaceuticals Inc., which was confirmed by the United States Bankruptcy Court for the Northern District of Texas on April 2, 2024, all of the Issuer's shares of its capital stock were canceled and extinguished effective April 5, 2024, and any rights of any holder in respect thereof were canceled without any recovery. F2 · derivative.exercise_date: The option was fully vested. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 16:20 UTC | IPI Legacy Liquidation Co IMPLQ · Entity 15659 | OtherStock Option (right to buy) · Derivative | 31,356 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001415889-24-010568 · form4-04092024_080446.xml · derivative · entry 1 Wilfong Diane E. · CIK 0001374988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,356 shares Expires 2029-11-20 F1 · kind: Pursuant to the First Amended Joint Plan of Liquidation of Impel Pharmaceuticals Inc., which was confirmed by the United States Bankruptcy Court for the Northern District of Texas on April 2, 2024, all of the Issuer's shares of its capital stock were canceled and extinguished effective April 5, 2024, and any rights of any holder in respect thereof were canceled without any recovery. F2 · derivative.exercise_date: The option was fully vested. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 18:39 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 13,222 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001209191-23-038603 · doc4.xml · derivative · entry 1 Wilfong Diane E. · CIK 0001374988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,222 Underlying: Common Stock · 13,222 shares Expires 2033-06-15 F1 · derivative.exercise_date: The option is 100% vested on June 16, 2024. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003825 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,060 Underlying: Common Stock · 1,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the yearly anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 565 | $86.36 | $48,793.40 |
DisclosureSEC source: 0001127602-23-003825 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,010 Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003825 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 20:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,244 | $84.02 | $104,520.88 |
DisclosureSEC source: 0001127602-23-002284 · form4.xml · nonDerivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,711 Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 20:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 4,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002284 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,955 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2020. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 20:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002284 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,855 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021 and March 10, 2022. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027390 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,924 Underlying: Common Stock · 318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 149 | $87.97 | $13,107.53 |
DisclosureSEC source: 0001127602-22-027390 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,502 Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027390 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 6,416 | $0.00 Strike: $63.91 | $0.00 |
DisclosureSEC source: 0001127602-22-025292 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,694 Underlying: Common Stock · 6,416 shares Expires 2031-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,416 | $83.50 | $535,736.00 |
DisclosureSEC source: 0001127602-22-025292 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,333 Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 6,416 | $63.91 | $410,046.56 |
DisclosureSEC source: 0001127602-22-025292 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 20:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 16,255 | $0.00 Strike: $72.70 | $0.00 |
DisclosureSEC source: 0001127602-22-024778 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,255 shares Expires 2027-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option have a three year vesting schedule. 33.33% vest on the first anniversary of the date of the grant. The balance will vest 8.33% quarterly thereafter until fully vested. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 20:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 16,255 | $79.25 | $1,288,208.75 |
DisclosureSEC source: 0001127602-22-024778 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,333 Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 20:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 16,255 | $72.70 | $1,181,738.50 |
DisclosureSEC source: 0001127602-22-024778 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022289 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,242 Underlying: Common Stock · 318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 148 | $65.28 | $9,661.44 |
DisclosureSEC source: 0001127602-22-022289 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,333 Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022289 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 21:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,479 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-020842 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,560 Underlying: Common Stock · 2,479 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 21:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,066 | $63.14 | $67,307.24 |
DisclosureSEC source: 0001127602-22-020842 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,163 Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 21:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,479 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-020842 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 17:06 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 12,789 | $0.00 Strike: $8.65 | $0.00 |
DisclosureSEC source: 0001209191-22-037961 · doc4.xml · derivative · entry 1 Wilfong Diane E. · CIK 0001374988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,789 Underlying: Common Stock · 12,789 shares Expires 2032-06-15 F1 · derivative.exercise_date: The option is 100% vested on June 16, 2023. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 317 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017330 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,039 Underlying: Common Stock · 317 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 148 | $60.74 | $8,989.52 |
DisclosureSEC source: 0001127602-22-017330 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,750 Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 317 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017330 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 5,610 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · derivative · entry 7 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,356 Underlying: Common Stock · 5,610 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 18,850 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · derivative · entry 6 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850 Underlying: Common Stock · 18,850 shares Expires 2032-03-10 F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,272 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · derivative · entry 5 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,746 Underlying: Common Stock · 1,272 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · derivative · entry 4 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,018 Underlying: Common Stock · 2,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 935 | $57.92 | $54,155.20 |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · nonDerivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,581 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 06, 2022 Filed Feb 9, 2022 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003845 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,043 Underlying: Common Stock · 1,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2022 Filed Feb 9, 2022 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 520 | $63.90 | $33,228.00 |
DisclosureSEC source: 0001127602-22-003845 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,219 Read SEC document |
| February 06, 2022 Filed Feb 9, 2022 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,864 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003845 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 394 | $67.34 | $26,531.96 |
DisclosureSEC source: 0001127602-22-002464 · form4.xml · nonDerivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,875 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002464 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,269 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 6, 2019. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002464 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,112 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2020, and March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 3,829 | $0.00 Strike: $66.36 | $0.00 |
DisclosureSEC source: 0001127602-21-023999 · form4.xml · derivative · entry 5 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,829 shares Expires 2027-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.